LigaChemBio to Receive Milestone Payment from SOTIO Biotech for Innovative ADC SOT106, On Track for IND Submission in 2026

·  Milestone follows successful development progress of SOT106, a potential best-in-class product candidate of SOTIO developed using LigaChem’s ADC platform.

·  SOT106 targets LRRC15, a promising target for sarcomas and other solid tumors with high unmet medical need.

·  SOTIO intends to submit global IND application for SOT106 in  the second half of 2026.

Daejeon, South Korea – February 9, 2026  - LigaChem Biosciences (141080KS, hereinafter ‘LigaChemBio’) announced today that it is scheduled to receive a milestone payment from SOTIO Biotech for the successful development of a product under the under the terms of the two companies’ ADC research collaboration initiated in November 2021. The drug candidate, SOT106, is an antibody-drug conjugate (ADC) targeting LRRC15 for the treatment of sarcomas and other LRRC15-positive malignancies. SOTIO plans to submit an IND application for a global clinical trial of SOT106 in the second half of 2026.

Initiated in 2021, the collaboration enables SOTIO to combine its proprietary antibodies with LigaChemBio’s ADC technology platform, including its proprietary conjugation technology ConjuAll™, to create novel therapeutics for the treatment of solid tumors. Under the terms of the multi-target agreement, LigaChemBio is eligible to receive upfront and potential milestone payments worth up to $1027.5 million, payable based on certain developments and regulatory achievements, plus royalties on net sales. SOTIO will be responsible for the research, development, manufacturing and commercialization of the ADC products.

Preclinical studies of SOT106 have demonstrated its potential as a best-in-class ADC to treat sarcomas. SOTIO has observed potent antitumor efficacy in mouse models of both soft tissue sarcoma and osteosarcoma that dramatically outperforms existing clinical benchmarks.

About SOTIO Biotech

SOTIO Biotech (SOTIO) is shaping the future of targeted cancer therapies by translating compelling science into patient benefit. The company is advancing an innovative pipeline of mono- and bispecific solid tumor ADC programs at various stages of preclinical development, including SOT106 for the treatment of LRRC15+ sarcomas and other solid tumors, and SOT109 for the treatment of colorectal cancer. SOT201, a next-generation PD-1-targeting immunocytokine, is being evaluated in the Phase 1 VICTORIA-01 study for patients with solid tumors. SOTIO is a member of the PPF Group. For more information, please visit the company’s website at www.sotio.com.